Back to top
more

Journey Medical (DERM)

(Delayed Data from NSDQ)

$5.40 USD

5.40
7,080

-0.06 (-1.10%)

Updated Jul 22, 2024 01:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (146 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Lilly (LLY) Q4 Earnings and Sales Top Estimates, Stock Up

by Zacks Equity Research

Eli Lilly's (LLY) Q4 earnings and sales beat estimates. Shares rise in pre-market trading.

Lilly (LLY) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are likely to have performed well. Let's see if these along with older products lead to an earnings beat for the company.

Lilly to Buy Dermira for $1.1B, Add Phase III Eczema Candidate

by Zacks Equity Research

Lilly (LLY) offers to buy Dermira for $1.1 billion to add the latter's late-stage candidate for atopic dermatitis/eczema, lebrikizumab.

The Zacks Analyst Blog Highlights: Agile Therapeutics, Air Industries, Dermira, Microbot Medical and Cassava Sciences

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Agile Therapeutics, Air Industries, Dermira, Microbot Medical and Cassava Sciences

Tirthankar Chakraborty headshot

Buy Multibagger Stocks as Odds of a Rally Are High in 2020

by Tirthankar Chakraborty

Multibagger stocks can make most of the bull run, courtesy of strong fundamentals and businesses that can multiply in a short span of time.

Pacira's (PCRX) Exparel Meets Key Goals in C-Section Study

by Zacks Equity Research

Pacira's (PCRX) phase IV CHOICE study on its lead drug Exparel in patients undergoing Cesarean section attains the primary as well as key secondary endpoints.

Moving Average Crossover Alert: Dermira

by Zacks Equity Research

Dermira, Inc. (DERM) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Will Dermira Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Dermira.

The Zacks Analyst Blog Highlights: LHC, Retrophin, Dermira and Merck & Co

by Zacks Equity Research

The Zacks Analyst Blog Highlights: LHC, Retrophin, Dermira and Merck & Co

Sanghamitra Saha headshot

Pharma Sector Tops in October: Best ETFs & Stocks

by Sanghamitra Saha

Pharma sector wins in October, making these ETFs and stocks winners.

Trade Deal Delay Unlikely to Hit U.S. Healthcare: 4 Picks

by Zacks Equity Research

The healthcare sector seems to be least affected by a protracted U.S.-China trade war. Stellar third-quarter earnings make the sector a hotbed for money.

Jazz Pharma (JAZZ) Q3 Earnings Beat, Xyrem Drives Sales

by Zacks Equity Research

Jazz Pharmaceuticals (JAZZ) beats third-quarter 2019 earnings and revenue estimates and raises its guidance for 2019.

Dermira (DERM) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Dermira (DERM) delivered earnings and revenue surprises of 24.29% and 4.18%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Aclaris Divests Rhofade to EPI Health for $55M, Shares Up

by Zacks Equity Research

Aclaris (ACRS) divests worldwide rights to its rosacea drug, Rhofade, to privately-held EPI Health as part of its restructuring program.

Dermira Starts Lebrikizumab Dosing in Late-Stage Eczema Study

by Zacks Equity Research

Dermira (DERM) starts a phase III program for evaluation of its monoclonal antibody candidate, lebrikizumab, in adolescents and adult patients with atopic dermatitis, the most common form of eczema.

Dermira (DERM) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Dermira (DERM) delivered earnings and revenue surprises of 63.33% and 95.12%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Dermira (DERM) Q2 Earnings Expected to Decline

by Zacks Equity Research

Dermira (DERM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Dermira (DERM) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Dermira (DERM) delivered earnings and revenue surprises of -13.74% and -6.77%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Dermira (DERM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

Dermira (DERM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Dermira (DERM) Catches Eye: Stock Jumps 12%

by Zacks Equity Research

Dermira (DERM) saw a big move last session, as its shares jumped nearly 12% on the day, amid huge volumes.

Company News For Mar 19, 2019

by Zacks Equity Research

Companies in the news are: OSTK, FIS, WP, EW and DERM

Implied Volatility Surging for Dermira (DERM) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Dermira (DERM) stock based on the movements in the options market lately.

Dermira (DERM) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Dermira (DERM) delivered earnings and revenue surprises of 20.20% and -10.38%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Dermira (DERM) Q3 Earnings Preview: What to Know Ahead of the Release

by Zacks Equity Research

Dermira (DERM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Dermira (DERM) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Dermira (DERM) delivered earnings and revenue surprises of 0.00% and 0.21%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?